A global Vet Syringe Pump Market study includes an in-depth analysis of important industry trends and dynamics, as well as market estimates and projections for major geographies and countries. The market study includes company profiles, size, product specs, product value, and capacity for
Posted by admin on Jun 9th, 2022
Sigyn Therapeutics (NASDAQ:SIGY – Get Rating) and Pulmonx (NASDAQ:LUNG – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valu
Permanent link to this press release:
Delete press release Edit press rele
Computer Glitches and Human Error Still Causing Insurance Headaches for Californians
Covered California and Medi-Cal share a computer system for eligibility and enrollment. Nearly a decade since the Affordable Care Act expanded coverage options in the s
The First and Only FDA-Cleared Device Available in the United States to Provide Hemodiafiltration Therapy to Dialysis Patients
SOUTH ORANGE, NJ, May 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros Inc. (Nasdaq: NEPH), a leading water technology company providing filtration
Dr. David Gu, director of HouFeng Diabetes & Hemodialysis Clinic, often receives patients who come in to relieve their renal pain. However, after examination, the vast majority of these patients have lower back pain caused by other factors such as muscle strain.
Kidneys are “si
"Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has."
Cureus is on a mission to change the long-standing paradigm of medical publishing, where submitting research can be costly, complex and time-consuming.
Permanent link to this press release:
Delete press release Edit press rele
SAN DIEGO, CA / ACCESSWIRE / May 23, 2022 / Plandai Biotechnology Inc. (OTC PINK:PLPL) (the "Company") today announced its entry into a non-binding letter of intent to enter into a new business through a proposed product and technology rights licensing agreement with the holder of rights to th
Stand-alone Blood Pump Business Model is expected to Enable Expanded Use and Increased Adoption of CytoSorb®
PRINCETON, N.J. , June 1, 2022 /PRNewswire/ -- CytoSorbents, Inc. (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and